267 related articles for article (PubMed ID: 21833176)
1. Stereoselective Inhibition of the hERG1 Potassium Channel.
Grilo LS; Carrupt PA; Abriel H
Front Pharmacol; 2010; 1():137. PubMed ID: 21833176
[TBL] [Abstract][Full Text] [Related]
2. The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.
Perissinotti L; Guo J; Kudaibergenova M; Lees-Miller J; Ol'khovich M; Sharapova A; Perlovich GL; Muruve DA; Gerull B; Noskov SY; Duff HJ
Mol Pharmacol; 2019 Aug; 96(2):259-271. PubMed ID: 31182542
[TBL] [Abstract][Full Text] [Related]
3. hERG1 channel activators: a new anti-arrhythmic principle.
Grunnet M; Hansen RS; Olesen SP
Prog Biophys Mol Biol; 2008; 98(2-3):347-62. PubMed ID: 19351523
[TBL] [Abstract][Full Text] [Related]
4. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
5. Nedd4-2-dependent ubiquitylation and regulation of the cardiac potassium channel hERG1.
Albesa M; Grilo LS; Gavillet B; Abriel H
J Mol Cell Cardiol; 2011 Jul; 51(1):90-8. PubMed ID: 21463633
[TBL] [Abstract][Full Text] [Related]
6. Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators.
Guo J; Durdagi S; Changalov M; Perissinotti LL; Hargreaves JM; Back TG; Noskov SY; Duff HJ
PLoS One; 2014; 9(9):e105553. PubMed ID: 25191697
[TBL] [Abstract][Full Text] [Related]
7. HERG1 channel agonists and cardiac arrhythmia.
Sanguinetti MC
Curr Opin Pharmacol; 2014 Apr; 15():22-7. PubMed ID: 24721650
[TBL] [Abstract][Full Text] [Related]
8. Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex.
Santini L; Duranti C; Palandri C; Giammarino L; Musumeci M; Carlucci L; Capitani C; Colasurdo R; Recchia F; Cerbai E; Coppini R; Arcangeli A
Front Pharmacol; 2023; 14():1237431. PubMed ID: 37767396
[No Abstract] [Full Text] [Related]
9. Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
Durdagi S; Randall T; Duff HJ; Chamberlin A; Noskov SY
BMC Pharmacol Toxicol; 2014 Mar; 15():14. PubMed ID: 24606761
[TBL] [Abstract][Full Text] [Related]
10. Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.
Atalar F; Acuner TT; Cine N; Oncu F; Yesilbursa D; Ozbek U; Turkcan S
Behav Brain Funct; 2010 May; 6():27. PubMed ID: 20507645
[TBL] [Abstract][Full Text] [Related]
11. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.
Grunnet M; Abbruzzese J; Sachse FB; Sanguinetti MC
Mol Pharmacol; 2011 Jan; 79(1):1-9. PubMed ID: 20876384
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced torsades de pointes: the evolving role of pharmacogenetics.
Fitzgerald PT; Ackerman MJ
Heart Rhythm; 2005 Nov; 2(2 Suppl):S30-7. PubMed ID: 16253929
[TBL] [Abstract][Full Text] [Related]
14. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
15. Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations.
Mousaei M; Kudaibergenova M; MacKerell AD; Noskov S
J Chem Inf Model; 2020 Dec; 60(12):6489-6501. PubMed ID: 33196188
[TBL] [Abstract][Full Text] [Related]
16. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
Farkas AS; Nattel S
Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
[TBL] [Abstract][Full Text] [Related]
17. Determinants of Isoform-Specific Gating Kinetics of hERG1 Channel: Combined Experimental and Simulation Study.
Perissinotti LL; De Biase PM; Guo J; Yang PC; Lee MC; Clancy CE; Duff HJ; Noskov SY
Front Physiol; 2018; 9():207. PubMed ID: 29706893
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
Garg V; Stary-Weinzinger A; Sachse F; Sanguinetti MC
Mol Pharmacol; 2011 Oct; 80(4):630-7. PubMed ID: 21743002
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Cubeddu LX
Curr Cardiol Rev; 2016; 12(2):141-54. PubMed ID: 26926294
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of interaction mechanism of hERG1 potassium channel with scorpion toxins BeKm-1 and BmTx3b.
Gunay BC; Yurtsever M; Durdagi S
J Mol Graph Model; 2020 May; 96():107504. PubMed ID: 31901677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
